Resolvyx Pharmaceuticals

... the end in inflammation

Board of Directors

The Resolvyx Board of Directors is comprised of:

Douglas Cole, MD General Partner, Flagship Ventures

Jean-Francois Formela, MD - Senior Partner, Atlas Venture

Keith Manchester, MD, Portfolio Manager, QVT Financial LP

George M. Milne, Jr., PhD - Venture Partner, Radius Ventures LLC

James Nichols, PhD - President and CEO, Resolvyx Pharmaceuticals

Gregory Weinhoff, MD - Partner, CHL Medical Partners

The Resolvin "many-to-one" approach will, for the first time, address the immune system redundancy as a major obstacle to identifying highly efficacious therapies for chronic inflammatory diseases.